Anticholinergics in the treatment of bronchial asthma


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The article reveals some aspects of managing patients with bronchial asthma (BA), in which the possibility of achieving complete control of the disease remains a difficult task, despite the use of the maximum amount of recommended basic therapy (medium/high doses of inhaled glucocorticosteroids - IGCS in combination with long-acting в2-agonists - LABA). The exclusion of an alternative diagnosis, the identification and elimination of various factors, including concomitant chronic diseases, are important components of the algorithm for managing a patient with an uncontrolled disease. The patient’s lack of adherence to the prescribed treatment and violation of the technique of inhalation maneuver can also be the causes of the ineffectiveness of BA treatment. Antileukotriene drugs, tiotropium bromide, biological and drugs can be used as additional therapy at different stages of treatment. The effectiveness of tiotropium delivered via Respimat device is determined by various clinical and functional aspects, such as an increase in external respiration function, a decrease in daily symptoms, a decrease in the risk of exacerbations, and an improvement in the quality of life and control of disease in general. Efficacy and good tolerability of tiotropium make it possible to use it in moderate and severe asthma as an addition to the therapy with IGCS/LABA, regardless of BA phenotype.

Full Text

Restricted Access

About the authors

Yu. G Belotserkovskaya

Russian Medical Academy of Continuous Professional Education

Email: belo-yuliya@yandex.ru
PhD, Associate Professor at the Department of Pulmonology

A. G Romanovskikh

Russian Medical Academy of Continuous Professional Education

I. P Smirnov

Russian Medical Academy of Continuous Professional Education

References

  1. GINA Report. Global Strategy for Asthma Management and Prevention. Updated 2019. The GINA reports are available on www.ginasthma.org
  2. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global Burden of Disease 2016 Disease and injury incidence and Prevalence Collaborators. Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. Lancet. 2017;390(10100):1211-59. Doi: 10.1016/ S0140-6736(17)32154-2.
  3. Demoly P., Paggiaro P., Plaza V., et al. Prevalence of asthma control among adults in France, Germany, Italy, Spain and the UK. Eur Respir Rev. 2009;18(112):105-12. doi: 10.1183/09059180.00001209.
  4. Vos T., Flaxman A.D., Naghavi M., et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012;380:2163-96. doi: 10.1016/S0140-6736(12)61729-2.
  5. Федеральные клинические рекомендации по диагностике и лечению бронхиальной астмы (проект 2018). www.pulmonology.ru. Российское респираторное общество (РРО). Клинические рекомендации по бронхиальной астме (частота пересмотра каждые три года). URL: http://spulmo.ru/obrazovatelnye-resursy/ federalnye-klinicheskie-rekomendatsii.
  6. Bateman E.D., Boushey H.A., Bousquet J., et al. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL study Am J Respir Crit Care Med. 2004;170(8):836-44.
  7. Sheehan WJ., Phipatanakul W. Difficult to Control Asthma: Epidemiology and its Link with Environmental Factors. Curr Opin Allergy Clin Immunol. 2015;15(5):397-401. Doi: 10.1097/ ACI.0000000000000195.
  8. Chung K.F., Wenzel S.E., Brozek J.L., et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J. 2014;43:343-73. doi: 10.1183/09031936.00202013.
  9. Cisneros S.C., Melero M.C., Almonacid S.C., et al. Guidelines for Severe Uncontrolled Asthma. Arch Bronconeumol. 2015;51:235-46.
  10. Suzuki T., Saito I., Adachi M., et al. Influence of patients' adherence to medication, patient background and physicians' compliance to the guidelines on asthma control. Yakugaku Zasshi. 2011;131(1):129-38.
  11. Molimard M., Raherison C., Lignot M., et al. Assessment of handling of inhaler devices in real life: an observational study in 3811 patients in primary care. J Aerosol Med. 2003;16:249-54.
  12. Lavorini F, Magnan A., Dubus J.C., et al. Effect of incorrect use of dry powder inhalers on management of patients with asthma and COPD. Respir Med. 2008;102:593-604.
  13. Choi J.H., Kim M.A., Park H.S. An update on the pathogenesis of the upper airways in aspirin-exacerbated respiratory disease. Curr Opin Allergy Clin Immunol. 2014;14:1-6. Doi: 10.1097/ ACI.0000000000000021.
  14. Harding S.M., Allen J.E., Blumin J.H., et al. Respiratory manifestations of gastroesophageal reflux disease. Ann N.Y Acad Sci. 2013;1300:43-52. doi: 10.1111/nyas.12231.
  15. Gibson PG. Obesity and asthma. Ann Am Thorac. Soc. 2013;10:38-42. Doi: 10.1513/ AnnalsATS.201302-038AW.
  16. Periyalil H.A., Gibson PG., Wood L.G. Immunometabolism in obese asthmatics: are we there yet? Nutrients. 2013;5:3506-30. doi: 10.3390/nu5093506.
  17. Julien J.Y, Martin J.G., Ernst P., et al. Prevalence of obstructive sleep apnea-hypopnea in severe versus moderate asthma. J Allergy Clin Immunol. 2009;124:371-76. Doi: 10.1016/j. jaci.2009.05.016.
  18. Wang G., Zhou T., Wang L., et al. Relationship betweencurrent psychological symptomsand future risk of asthma outcomes: a 12-month prospective cohort study. J Asthma. 2011;48:1041-50. doi: 10.3109/02770903.2011.631238.
  19. Pietinalho A., Pelkonen A., Rytila P Linkage between smoking and asthma. Allergy. 2009;64:1722-27. doi: 10.1111/j.1398-9995.2009.02208.x.
  20. Thomson N.C., Chaudhuri R., Heaney L.G., et al. Clinical outcomes and inflammatory biomarkers in current smokers and exsmokers with severe asthma. J AllergyClin. Immunol. 2013;131:1008 16. doi: 10.1016/j.jaci.2012.12.1574
  21. Kerstjens H.A., Moroni-Zentgraf P, Tashkin D.P, et al. Tiotropium improves lung function, exacerbation rate, and asthma control, independent of baseline characteristics including age, degree of airwayobstruction, and allergic status. Respir Med. 2016;117:198-206. Doi: 10.1016/j. rmed.2016.06.013.
  22. Casale T.B., Bateman E.D., Aalbers R., et al. Once-daily tiotropiumRespimat add-on therapy improves lung function and asthma control in moderate symptomatic asthma, independent of baseline characteristics. Eur Respir J. 2017;50:PA647.
  23. Kerstjens H.A., Engel M., Dahl R., et al. Tiotropium in Asthma Poorly Controlled with Standard Combination Therapy N Engl J Med. 2012;67:1198-207.
  24. Чучалин А.Г, Авдеев С.Н., Айсанов З.Ридр. от лица Российского респираторного общества. Согласованные рекомендации по применению антихолинергического препарата длительного действия тиотропия в терапии бронхиальной астмы. Пульмонология. 2675;25(2):743-56
  25. Kerstjens H.A., Disse B., Schroder-Babo W., et al. Tiotropium improveslung function in patients with severe uncontrolled asthma: a randomizedcontrolled trial. J Allergy Clin Immunol. 2611;120(2):360-14. Doi: 16.1616/j. jaci.2611.64.039.
  26. Kerstjens H.A., Casale T.B., Bleecker E.R., et al. Tiotropium or salmeterolas add-on therapy to inhaled corticosteroids for patients with moderatesymptomatic asthma: two replicate, double-blind, placebo-controlled, parallel-group, active-comparator, randomised trials. Lancet. Respir Med. 2615;3(5):367-76. Doi: 16.1616/ S2213-2666(15)66631-4.
  27. Paggiaro P, Halpin D.M., Buhl R., et al. The effect of tiotropium in symptomatic asthma despite low- to medium-dose inhaled corticosteroids:a randomized controlled trial. J Allergy Clin Immunol Pract. 2676;4(7):764-73. Doi: 76.7676/j. jaip.2615.68.017.
  28. Ohta K., Ichinose M., Tohda Y, et al. Longterm once-daily tiotropiumRespimat® is well tolerated and maintains efficacy over 52 weeks in patients with symptomatic asthma in Japan: a randomised, placebo controlled study. PLoS One. 2615;16(4):e6124162. doi: 16.1371/journal. pone.6124162.
  29. Rodrigo G.J., Castro-Rodriguez J.A. What is the role of tiotropium in asthma? A systematic review with metaanalysis. Chest. 2015;147(2):300-96. doi: 16.1378/chest.14-1698.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2019 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies